Anlotinib

Property	Information
Drug Name	Anlotinib
FDA Approval	Under investigation; not yet FDA-approved
Used for	Various cancers including Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, and Renal Cell Carcinoma; being investigated for Glioblastoma Multiforme (GBM)
Clinical Trial Phase	Phase 2 and 3 (for different cancers); early-stage trials for GBM
Clinical Trial Explanation	Not specified
Common Side Effects	Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction
OS without	Median overall survival for GBM is typically 15-17 months from diagnosis, or 8 months from recurrence
OS with	Preliminary data suggest potential improvement in overall survival, but specific figures for GBM are under investigation
PFS without	Data not specified
PFS with	Preliminary data suggest potential improvement in progression-free survival, but specific figures for GBM are under investigation
Usefulness Rating	4
Usefulness Explanation	Early clinical trials show promising results in improving overall survival and progression-free survival in various cancers, including potential benefits for GBM. Ongoing trials will provide more definitive data.
Toxicity Level	3
Toxicity Explanation	Generally well-tolerated but associated with some common side effects like hypertension and fatigue; ongoing trials will provide more detailed safety data for GBM

Notes: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.

Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.

Anlotinib is not yet FDA-approved and is currently available under investigation in clinical trials. Common side effects include hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, and thyroid dysfunction. Further research and clinical data will help establish its role in the treatment of GBM and other cancers.

For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided.

Links: https://www.cancernetwork.com/view/anlotinib-showed-efficacy-safety-patients-glioblastoma, https://www.sciencedirect.com/science/article/abs/pii/S0923753419305329, https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=Anlotinib&cntry=&state=&city=&dist=

From Ben Williams Book: Not specified

Loading comments...